Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1992 Sep;35(5):342–346. doi: 10.1007/BF01741148

Tumor necrosis factor α modifies resistance to interferon α in vivo: First clinical data

Thomas Moritz 1,✉, Otto Kloke 1, Marianne Nagel-Hiemke 1, Gerd Kummer 1, Ursula B Wandl 1, Bertram Opalka 3, Birgit Plappert 1, Joachim Kempeni 4, Siegfried Seeber 1, Norbert Niederle 5
PMCID: PMC11038589  PMID: 1394338

Abstract

Patients with Philadelphia-positive chronic-phase chronic myelogenous leukemia (CML) resistant to interferon (IFN) α were treated in a phase I/II study with recombinant human tumor necrosis factor α to overcome IFNα resistance. Doses of 40, 80, 120 or 160 µg/m2 TNFα were given as 2-h infusions on 5 consecutive days every 3 weeks. IFNα (4 × 106 IU/m2 s.c., daily) treatment was continued. Six patients were treated, completing 1–24 (median, 12) treatment cycles. Five of the six patients achieved partial hematological remission, while the remaining patient had to stop treatment because of WHO grade 4 thrombocytopenia following the first TNFα cycle. No complete hematologic remission or cytogenetic improvement was seen. Side-effects were similar to those described for both substances alone. Maximum tolerable TNF doses usually varied between 80 µg/m2 and 160 µg/m2. To examine possible pathways of TNF activity in these patients, interferon receptor status and (2′–5′)-oligoadenylate synthetase levels were examined in peripheral blood mononuclear cells. Both parameters remained unchanged during TNFα treatment. These preliminary data point to significant clinical efficacy of additionally applyed TNFα in IFNα-resistant CML patients.

Key words: Tumor necrosis factor, Interferon α

References

  • 1.Alimena G, Morra E, Lazzarino M, Liberata AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F. Interferon alpha-2b therapy for Ph′-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1988;72:642. [PubMed] [Google Scholar]
  • 2.Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W. Human tumour xenografts treated with recombinant human tumor necrosis factor alone or in combinations with interferons. Cancer Res. 1986;46:3990. [PubMed] [Google Scholar]
  • 3.Bolton AE, Hunter WM. The labeling of proteins to high specific activities by conjugation to a125I-containing alkylating agent: application to the radioimmunoassay. Biochem J. 1974;133:529. doi: 10.1042/bj1330529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987;5:1942. doi: 10.1200/JCO.1987.5.12.1942. [DOI] [PubMed] [Google Scholar]
  • 5.Clauss IM, Vandenplas B, Wathelet MG, Dorval C, Delforge A, Content J, Stryckmans P, Huez GA. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-α treatment. Blood. 1990;76:2337. [PubMed] [Google Scholar]
  • 6.Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, Proefrock A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:137. doi: 10.1007/BF00253968. [DOI] [PubMed] [Google Scholar]
  • 7.deMel WCP, Hoffbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshaguru K. Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2′,5′-oligoadenylate system and clinical response. Br J Haematol. 1990;74:452. doi: 10.1111/j.1365-2141.1990.tb06334.x. [DOI] [PubMed] [Google Scholar]
  • 8.Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW. A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol. 1989;7:1545. doi: 10.1200/JCO.1989.7.10.1545. [DOI] [PubMed] [Google Scholar]
  • 9.Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1989;7:298. doi: 10.1200/JCO.1989.7.3.298. [DOI] [PubMed] [Google Scholar]
  • 10.Kasid A, Director EP, Rosenberg SA. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol. 1989;143:736. [PubMed] [Google Scholar]
  • 11.Kloke O, Niederle N. Development and mechanisms of interferon resistance. Cancer Treat Rev. 1990;17(Suppl A):81. doi: 10.1016/0305-7372(90)90019-c. [DOI] [PubMed] [Google Scholar]
  • 12.Kloke O, Moritz T, Matika S, Kummer G, Niederle N. Reversal of resistance to interferon alfa by the addition of tumor necrosis factor: preclinical and clinical observations. Blut. 1988;57:223. [Google Scholar]
  • 13.Langer JA, Pestka S. Procedures for studying binding of interferon to human cells in suspension cultures. Methods Enzymol. 1986;119:305. doi: 10.1016/0076-6879(86)19046-x. [DOI] [PubMed] [Google Scholar]
  • 14.Merlin G, Revel M, Wallach D. The interferon-induced enzyme oligo-isoadenylate synthetase: rapid determination of its in vitro products. Anal Biochem. 1981;110:190. doi: 10.1016/0003-2697(81)90134-2. [DOI] [PubMed] [Google Scholar]
  • 15.Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, Schmidt CG. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunol Immunother. 1989;29:144. doi: 10.1007/BF00199290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Moritz T, Weissmann B, Grünewald B, Hust H, Kummer G, Niederle N. Induction of 2′–5′oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia. Mol Biother. 1992;4:97. [PubMed] [Google Scholar]
  • 17.Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980;107:220. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  • 18.Nagel-Hiemke M, Hiemke C, Kummer K, Moritz T, Müller H, Niederle N. Mechanisms involved in the increase of leukocyte counts following tumor necrosis factor (TNF) administration in patients with chronic myelogenous leukemia (CML) Blut. 1990;61:192. [Google Scholar]
  • 19.Nedwin GE, Svedersky LP, Bringham TS, Palladino MA, Goeddel DV. Effect of interleukin 2, interferon-gamma and mitogens on the production of tumor necrosis factors alfa and beta. J Immunol. 1985;135:2493. [PubMed] [Google Scholar]
  • 20.Niederle N, Kloke O, Osieka R, Wandl UB, Opalka B, Schmidt CG. Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol. 1987;14(Suppl 2):29. [PubMed] [Google Scholar]
  • 21.Niederle N, Moritz T, Kloke O, Wandl U, May D, Becher R, Franz T, Opalka B, Seeber S. Interferon alpha-2b in acute and chronic phase CML: initial response and long-term results in 54 patients. Eur J Cancer. 1991;27(Suppl 4):7. doi: 10.1016/0277-5379(91)90556-s. [DOI] [PubMed] [Google Scholar]
  • 22.Opalka B, Wandl UB, Becher B, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon-gamma. Blood. 1991;78:2188. [PubMed] [Google Scholar]
  • 23.Otto U, Conrad S, Schneider AW, Kempeni J, Schlick E, Klosterhalfen H. Combined therapy with TNFα and α-2b-interferon: apromising approach to metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 1990;116(Suppl II):1057. [Google Scholar]
  • 24.Retsas S, Leslie M, Bottomley D. Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma. Br Med J. 1989;298:1290. doi: 10.1136/bmj.298.6683.1290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to α-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res. 1986;46:4848. [PubMed] [Google Scholar]
  • 26.Stella CC, Cazzola M, Ganser A, Dezza L, Völkers B, Ascari E. Human recombinant tumor necrosis factor alpha (TNF-alpha) inhibits the growth of hemopoietic progenitor cells from chronic myelogenous leukemia. Immunobiology. 1987;175:73. [Google Scholar]
  • 27.Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62:689. [PubMed] [Google Scholar]
  • 28.Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha-A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065. doi: 10.1056/NEJM198604243141701. [DOI] [PubMed] [Google Scholar]
  • 29.Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B. Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med. 1986;164:1206. doi: 10.1084/jem.164.4.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wiedenmann B, Reichardt P, Räth U, Theilmann L, Schüle B, Ho AD, Schlick E, Kempeni J, Hunstein W, Kommerell B. Phase-I trial of intravenous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol. 1989;115:189. doi: 10.1007/BF00397922. [DOI] [PubMed] [Google Scholar]
  • 31.Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA. 1983;80:5397. doi: 10.1073/pnas.80.17.5397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Wong GHW, Goeddel DV. Tumour necrosis factors α and β inhibit virus replication and synergise with gamma interferon. Nature. 1986;323:819. doi: 10.1038/323819a0. [DOI] [PubMed] [Google Scholar]
  • 33.von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H. Successful treatment of rIFN-α2b-antibody positive patients with natural IFN-α. Lancet. 1988;1:882. doi: 10.1016/s0140-6736(88)91628-5. [DOI] [PubMed] [Google Scholar]
  • 34.Yoffe G, Blick M, Kantarjian HM. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood. 1987;69:961. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES